All PlansCoverageMedium impact
Hematopoietic Cell Transplantation for Primary Amyloidosis or Waldenstrom's Macroglobulinemia
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Medical Policy
We identified it
Jun 20, 2026
Summary
This is a new medical policy establishing coverage criteria for hematopoietic cell transplantation (bone marrow/stem cell transplant) for treating primary amyloidosis and Waldenstrom's macroglobulinemia. The policy defines both autologous and allogeneic transplant procedures and outlines the medical conditions and treatment approaches covered.
Action Required
Immediately: Review this new policy with oncology and hematology providers to understand coverage criteria for hematopoietic cell transplantation claims. Update prior authorization procedures to align with the defined medical necessity criteria for primary amyloidosis and Waldenstrom's macroglobulinemia cases. Ensure documentation requirements are met before submitting transplant-related claims.